• Giandomenico Roviello, Silvia Paola Corona, Giovanni Bozza, Michele Aieta, Daniele Generali, Maria Grazia Rodriquenz, Anna Maria Mileo, Marco Imperatori, Anna Ianza, Raffaele Conca, and Navid Sobhani.
• a Division of Medical Oncology, Department of Onco-Hematology , IRCCS-CROB, Referral Cancer Center of Basilicata , Rionero, Vulture , Italy.
• Expert Opin Investig Drugs. 2018 May 1; 27 (5): 507-512.

IntroductionRenal cell carcinoma (RCC) accounts for 2-3% of all solid tumors. Expression of the receptor for the vascular endothelial growth factor (VEGF) is one of the most common features of RCC.Areas CoveredLenvatinib is a novel multi-kinase inhibitor that has been studied in several solid tumors. It has shown promising results in the treatment of RCC, especially when combined with everolimus, In this review, we summarize the available data of lenvatinib for the treatment of advanced/metastatic renal cell carcinoma.Expert OpinionLenvatinib in combination with everolimus has provided encouraging results in both clinical and laboratory investigations showing that blocking angiogenesis and the mTOR signalling pathway could be a remarkable approach for treating RCC. As an additive to this type of approach it would be interesting in future clinical settings testing also the combination of lenvatinib and everolimus with immune-therapy.

29 keywords...

hide…